Anti-Müllerian hormone: A better marker of ovarian damage from cyclophosphamide

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1305-1310

  Clowse, Megan E B ^a   Harward, Lindsey ^b   Criscione Schreiber, Lisa ^a   Pisetsky, David ^a   Copland, Susannah ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FOLLITROPIN; GONADORELIN; MUELLERIAN INHIBITING FACTOR;

CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE MARKER; FERTILITY; FOLLITROPIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MENOPAUSE; MENSTRUATION; NOTE; OOCYTE; OVARY DISEASE; OVARY FUNCTION; PRIORITY JOURNAL; RHEUMATIC DISEASE;

AGE FACTORS; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; CYCLOPHOSPHAMIDE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OVARY; PRIMARY OVARIAN INSUFFICIENCY; RHEUMATIC DISEASES;

EID: 84860442721     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34431     Document Type: Note

References (26)

1. Gonzalez LA, McGwin G Jr, Durán S, Pons-Estel GJ, Apte M, Vilá LM, et al. Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII). Ann Rheum Dis 2008; 67: 1170-3.
2. Holle JU, Gross WL, Latza U, Nolle B, Ambrosch P, Heller M, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011; 63: 257-66.
3. Hensley ML, Reichman BS,. Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Crit Rev Oncol Hematol 1998; 28: 121-8.
4. Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK,. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004; 13: 569-74.
5. Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 2002; 29: 2571-6.
6. Brunner HI, Bishnoi A, Barron AC, Houk LJ, Ware A, Farhey Y, et al. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 2006; 15: 198-206.
7. Katsifis GE, Tzioufas AG,. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 2004; 13: 673-8.
8. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
9. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-4.
10. Visser JA, de Jong FH, Laven JS, Themmen AP,. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction 2006; 131: 1-9.
11. La Marca A, Stabile G, Artenisio AC, Volpe A,. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006; 21: 3103-7.
12. Li HW, Wong CY, Yeung WS, Ho PC, Ng EH,. Serum anti-mullerian hormone level is not altered in women using hormonal contraceptives. Contraception 2011; 83: 582-5.
13. La Marca A, Volpe A,. AntiMullerian serum levels during pregnancy. Clin Endocrinol (Oxf) 2006; 64: 715-6.
14. Seifer DB, Baker VL, Leader B,. Age-specific serum anti-Mullerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril 2011; 95: 747-50.
15. Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008; 93: 3478-83.
16. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA,. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006; 21: 2583-92.
17. Anderson RA, Cameron DA,. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011; 96: 1336-43.
18. Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008; 26: 286-95.
19. Clowse ME, Copland SC, Hsieh TC, Chow SC, Hoffman GS, Merkel PA, et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2011; 63: 1777-81.
20. Browne H, Armstrong A, Decherney A, Babb R, Illei G, Segars J, et al. Assessment of ovarian function with anti-Mullerian hormone in systemic lupus erythematosus patients undergoing hematopoietic stem cell transplant. Fertil Steril 2009; 91: 1529-32.
21. Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, Fehm T, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus 2011; 20: 1193-7.
22. Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Lossl K, Andersen AN,. Dynamics and mechanisms of chemotherapyinduced ovarian follicular depletion in women of fertile age. Fertil Steril 2010; 94: 156-66.
23. Copland SC, Clowse MEB,. Use of GnRH agonists for prevention of chemotherapy-induced gonadotoxicity. In:, Donnez J, Kim SS, editors. Principles and practice of fertility preservation. Cambridge: Cambridge University Press; 2011. p. 239-49.
24. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ,. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005; 52: 2761-7.
25. Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009; 18: 311-9.
26. Hickman RA, Gordon C,. Causes and management of infertility in systemic lupus erythematosus. Rheumatology (Oxford) 2011; 50: 1551-8.